AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed

On September 8, 2026, CNBC reported that AstraZeneca PLC (NYSE: AZN ) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary disease. It shows the treatment reduced moderate and severe flare-ups by roughly 30% across a broad patient population, reinforcing the company's forecast that the drug could generate more than $5 billion in peak annual sales. The biologic, which blocks the inflammatory protein IL-33, is under priority review at the FDA with a decision expected in the first quarter of 2027. AstraZeneca believes it could reach a broader group of COPD patients than existing biologics that only target those with high eosinophil counts.

Tozorakimab could address a major broader COPD population than competing biologics. The two late-stage trials showed that tozorakimab reduced moderate-to-severe COPD exacerbations by 29% to 34%, with benefits across patients regardless of eosinophil levels, smoking status, or disease severity. The broad efficacy could give AstraZeneca PLC (NYSE: AZN ) access to patients who fall outside the populations currently targeted by competing biologics such as Regeneron and Sanofi's Dupixent and GSK's Nucala. The highest-eosinophil subgroup saw a particularly strong 43% reduction in exacerbations, further supporting the drug's potential clinical differentiation.

The results solidify AstraZeneca's respiratory growth pipeline. Tozorakimab gives the business another potential blockbuster as AstraZeneca targets $80 billion in annual revenue by 2030. CEO Pascal Soriot said the drug's commercial potential could exceed the company's previously raised $5 billion peak-sales estimate. It shows the size of the COPD market and the drug's potential use across the patient population. The successful trials give investors a potentially real future revenue contributor beyond AstraZeneca's existing medicines.

AstraZeneca can add to an already-growing respiratory and oncology franchise. The company's oncology and respiratory portfolio made $14.1 billion in first-half 2026 revenue, up 15% year over year. Hence, Tozorakimab would enter an established commercial platform with significant experience selling specialty medicines to respiratory patients. Strong existing growth could give AstraZeneca time to develop the drug's market opportunity while other products generate revenue and cash flow.

Tozorakimab still faces a significant regulatory hurdle before AstraZeneca PLC (NYSE: AZN ) can monetize the opportunity. The FDA has not yet approved the drug, and AstraZeneca expects a decision in the first quarter of 2027. Priority review can shorten the regulatory process, but it does not guarantee approval. Any regulatory concerns or delays could push back the launch and postpone the revenue contribution that investors expect from the potential blockbuster.